DiaSorin launches LIAISON® N-TACT® PTH II Assay (available outside the US only)


DiaSorin announces the release of the LIAISON® N-TACT® PTH II Assay for the determination of parathyroid hormone levels. The LIAISON® N-TACT® PTH II Assay is a chemiluminescent immunoassay for the quantitative determination of intact PTH in Serum and EDTA-plasma, offering excellent precision, accuracy and sensitivity. 
This new version of DiaSorin’s current LIAISON® N-TACT® PTH offers improved linearity and maintains low cross–reactivity to 7-84 PTH and other inactive fragments (relatively lower than other intact second generation competitive offerings) which unable a better patient  management; Assay performance is not affected by high levels of common interfering substances (i.e. cholesterol, triglycerides and bilirubin); A new specimen diluent for high patient samples is also available. 
The combination of analytical excellence and inclusion into DiaSorin’s unique Bone and Mineral menu (LIAISON® 25-OH Vitamin D TOTAL, LIAISON® 1-84 PTH, LIAISON® BAP OSTASE® and LIAISON® OSTEOCALCIN) provides convenience and accuracy of results.
DiaSorin offers a unique menu for assessing and monitoring patients with Bone and Mineral disorders, among many other specialty product lines, enabling laboratories to manage workflow with quality assays in one single platform.